Mitigating the risk of transfusion‐transmitted infections with vector‐borne agents solely by means of pathogen reduction
Open Access
- 21 June 2022
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 62 (7) , 1388-1398
Abstract
Background: This study evaluated whether pathogen reduction technology (PRT) in plasma and platelets using amotosalen/ultraviolet A light (A/UVA) or in red blood cells using amustaline/glutathione (S‐303/GSH) may be used as the sole mitigation strategy preventing transfusion‐transmitted West Nile (WNV), dengue (DENV), Zika (ZIKV), and chikungunya (CHIKV) viral, and Babesia microti, Trypanosoma cruzi, and Plasmodium parasitic infections.Methods: Antibody (Ab) status and pathogen loads (copies/mL) were obtained for donations from US blood donors testing nucleic acid (NAT)‐positive for WNV, DENV, ZIKV, CHIKV, and B. microti. Infectivity titers derived from pathogen loads were compared to published PRT log10 reduction factors (LRF); LRFs were also reviewed for Plasmodium and T. cruzi. The potential positive impact on donor retention following removal of deferrals from required questioning and testing for WNV, Babesia, Plasmodium, and T. cruzi was estimated for American Red Cross (ARC) donors.Results: A/UVA and S‐303/GSH reduced infectivity to levels in accordance with those recognized by FDA as suitable to replace testing for all agents evaluated. If PRT replaced deferrals resulting from health history questions and/or NAT for WNV, Babesia, Plasmodium, and T. cruzi, 27,758 ARC donors could be retained allowing approximately 50,000 additional donations/year based on 1.79 donations/donor for calendar year 2019 (extrapolated to an estimated 125,000 additional donations nationally).Conclusion: Pathogen loads in donations from US blood donors demonstrated that robust PRT may provide an opportunity to replace deferrals associated with donor questioning and NAT for vector‐borne agents allowing for significant donor retention and likely increased blood availability.Keywords
This publication has 62 references indexed in Scilit:
- Genomic Assays for Identification of Chikungunya Virus in Blood Donors, Puerto Rico, 2014Emerging Infectious Diseases, 2015
- Keeping Blood Transfusion Safe From West Nile Virus: American Red Cross Experience, 2003 to 2012Transfusion Medicine Reviews, 2015
- Inactivation of dengue virus in plasma with amotosalen and ultraviolet A illuminationTransfusion, 2014
- Photochemical Inactivation of Chikungunya Virus in Human Apheresis Platelet Components by Amotosalen and UVA LightThe American Journal of Tropical Medicine and Hygiene, 2013
- Dengue in the context of “safe blood” and global epidemiology: to screen or not to screen?Transfusion, 2012
- Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto RicoTransfusion, 2012
- Characterization of the functional requirements of West Nile virus membrane fusionJournal of General Virology, 2009
- Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La RéunionTransfusion, 2009
- Transfusion‐associated transmission of West Nile virus, United States 2003 through 2005Transfusion, 2006
- Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation functionTransfusion, 2006